- CNS Pharmaceuticals, Inc CNSP shares gained after the company disclosed the stock purchase by CEO John M Climaco and director Jerzy Gumulka.
- Climaco purchased 15,000 shares at an average price of $0.69 per share on April 14, and director Gumulka bought 7,173 shares at an average price of $0.74 on April 17.
- CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for treating primary and metastatic cancers of the brain and central nervous system.
- Price Action: CNSP shares traded higher by 36.20% at $3.20 on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
